CJC-1295 (No DAC)

Description

Research Peptide Compound

Product Classification: Research Use Only (RUO)

Concentration: 10 mg per vial

Form: Sterile Lyophilized Powder

Purity: ≥99% (HPLC-tested batches)

Storage: Store at −20 °C in a sealed, light-protected container

Packaging: Laboratory glass vial with protective sleeve

Product Overview

CJC-1295 (No DAC) is a synthetic peptide analog investigated for its interaction with growth hormone-releasing hormone (GHRH) receptor pathways in controlled laboratory research environments.

Unlike DAC-modified variants, this formulation does not contain Drug Affinity Complex (DAC) technology and is therefore studied for its shorter-duration signaling characteristics and pulsatile endocrine-response profile.

Scientific literature has explored CJC-1295 (No DAC) in relation to pituitary signaling, pulsatile growth hormone dynamics, insulin-like growth factor-1 (IGF-1) regulation, and peptide-mediated endocrine communication systems.

This material is supplied strictly for laboratory and analytical research purposes.

Intended Research Applications

This compound may be utilized in controlled laboratory environments for investigation into:

Growth hormone-releasing hormone (GHRH) signaling pathways
Pulsatile endocrine-response mechanisms
IGF-1-associated signaling research
Pituitary and metabolic pathway investigations
Short-duration peptide signaling dynamics
Peptide-based endocrine modulation research

Important Notice

FOR RESEARCH USE ONLY.

This product is not intended for human consumption, veterinary application, therapeutic use, or diagnostic purposes.

Products distributed by Lonestar Labs are intended solely for qualified laboratory professionals and authorized research institutions operating in accordance with applicable laws and regulations.

This compound is not a dietary supplement, pharmaceutical product, or approved drug product and must not be utilized in food, cosmetic, or human/veterinary applications.

These statements have not been evaluated by the U.S. Food and Drug Administration (FDA). This product is not intended to diagnose, treat, cure, or prevent any disease or medical condition.

Buyer assumes full responsibility for proper handling, storage, research application, and regulatory compliance.

Scientific Overview

Abstract

CJC-1295 (No DAC) is a modified GHRH analog investigated for its short-acting interaction with endocrine signaling pathways associated with growth hormone release and IGF-1 regulation.

Due to the absence of DAC modification, this investigational peptide is commonly studied for more transient signaling behavior compared with extended-duration GHRH analogs.

Published laboratory research has explored its relationship to pituitary-response dynamics, pulsatile hormone signaling, metabolic pathways, and peptide-mediated endocrine regulation systems.

Biological & Mechanistic Research Pathways

1. GHRH Receptor Signaling

CJC-1295 (No DAC) has been investigated for its interaction with growth hormone-releasing hormone receptors involved in pituitary-associated endocrine pathways.

Experimental studies have explored how transient peptide signaling may influence pulsatile growth hormone-release dynamics and downstream endocrine communication systems.

2. Pulsatile Hormone Signaling Research

The shorter-duration activity profile of non-DAC formulations has generated interest in laboratory models evaluating pulsatile endocrine-response behavior and peptide signaling timing characteristics.

Research continues to examine how signaling duration may influence endocrine pathway modulation.

3. IGF-1 Regulatory Pathways

Scientific investigations have explored relationships between GHRH-associated signaling and insulin-like growth factor-1 (IGF-1) pathway activity.

Preclinical studies continue to evaluate endocrine-response mechanisms associated with peptide-mediated hormonal communication systems.

4. Metabolic & Endocrine Research

Published literature has explored the relationship between GHRH-pathway activity and broader endocrine signaling systems involving metabolism, hormonal regulation, and peptide-mediated communication pathways.

These investigations remain experimental and continue to evolve within endocrine research environments.

Pharmacokinetic & Structural Notes

Compound Type: Modified synthetic GHRH analog
DAC Status: No Drug Affinity Complex (DAC) modification
Research Interest: Shorter-duration and pulsatile signaling characteristics
Storage Stability: Sensitive to heat and light exposure; frozen storage recommended
Research Handling: Reconstitution should only be performed in appropriate sterile laboratory environments

Research Summary

CJC-1295 (No DAC) remains an important investigational peptide within endocrine and metabolic research due to its short-acting GHRH receptor activity and pulsatile signaling profile.

Its investigational applications continue to generate interest in laboratory studies involving pituitary signaling, IGF-1 dynamics, endocrine modulation, and peptide-mediated hormone pathway research.

As peptide-based endocrine science continues to evolve, CJC-1295 (No DAC) remains a valuable research compound for controlled laboratory investigations involving transient hormonal signaling systems.